CN1318402C - 用作金属蛋白酶抑制剂的吡咯烷－2－羧酸酰肼衍生物 - Google Patents

用作金属蛋白酶抑制剂的吡咯烷－2－羧酸酰肼衍生物 Download PDF

Info

Publication number
CN1318402C
CN1318402C CNB018130488A CN01813048A CN1318402C CN 1318402 C CN1318402 C CN 1318402C CN B018130488 A CNB018130488 A CN B018130488A CN 01813048 A CN01813048 A CN 01813048A CN 1318402 C CN1318402 C CN 1318402C
Authority
CN
China
Prior art keywords
pyrrolidine
sulfonyl
carboxylic acid
hydrazide
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018130488A
Other languages
English (en)
Chinese (zh)
Other versions
CN1443163A (zh
Inventor
约翰内斯·埃比
亨丽埃塔·德姆洛
埃里克·阿尔吉里斯·基塔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1443163A publication Critical patent/CN1443163A/zh
Application granted granted Critical
Publication of CN1318402C publication Critical patent/CN1318402C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CNB018130488A 2000-07-19 2001-07-11 用作金属蛋白酶抑制剂的吡咯烷－2－羧酸酰肼衍生物 Expired - Fee Related CN1318402C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00114948.3 2000-07-19
EP00114948 2000-07-19

Publications (2)

Publication Number Publication Date
CN1443163A CN1443163A (zh) 2003-09-17
CN1318402C true CN1318402C (zh) 2007-05-30

Family

ID=8169225

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018130488A Expired - Fee Related CN1318402C (zh) 2000-07-19 2001-07-11 用作金属蛋白酶抑制剂的吡咯烷－2－羧酸酰肼衍生物

Country Status (18)

Country Link
US (1) US6444829B1 (enExample)
EP (1) EP1317428B1 (enExample)
JP (1) JP2004504298A (enExample)
KR (1) KR100580056B1 (enExample)
CN (1) CN1318402C (enExample)
AR (1) AR033543A1 (enExample)
AT (1) ATE323673T1 (enExample)
AU (1) AU2001276396A1 (enExample)
BR (1) BR0112543A (enExample)
CA (1) CA2415665A1 (enExample)
DE (1) DE60118941T2 (enExample)
ES (1) ES2261443T3 (enExample)
MX (1) MXPA03000363A (enExample)
PA (1) PA8522401A1 (enExample)
PE (1) PE20020339A1 (enExample)
UY (1) UY26844A1 (enExample)
WO (1) WO2002006224A1 (enExample)
ZA (1) ZA200300172B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589997B2 (en) * 2001-06-29 2003-07-08 North Shore-Long Island Jewish Health System Small-molecule modulators of hepatocyte growth factor/scatter factor activities
CN1294120C (zh) * 2003-10-21 2007-01-10 山东大学 吡咯烷类基质金属蛋白酶抑制剂及其应用
AT509045B1 (de) 2010-01-29 2011-06-15 Planta Naturstoffe Vertriebsges M B H Verbindungen zur behandlung von asthma bronchiale
CN103145572A (zh) * 2013-03-20 2013-06-12 康化（上海）新药研发有限公司 天然产物氯化γ-正缬氨酸盐酸盐的不对称合成方法
CN105712910B (zh) * 2016-03-08 2017-06-06 北京化工大学 （n‑芳基亚磺酰基）磺酰肼及其制备方法
WO2021029158A1 (ja) * 2019-08-09 2021-02-18 サンアプロ株式会社 スルホンアミド化合物、非イオン系光酸発生剤、およびフォトリソグラフィー用樹脂組成物
CN113030292A (zh) * 2021-01-29 2021-06-25 京博农化科技有限公司 一种对三氟甲氧基苯胺基甲酰肼含量的分析方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US493333A (en) * 1893-03-14 Air-heating furnace
CN1232451A (zh) * 1996-08-28 1999-10-20 普罗克特和甘保尔公司 取代的环状胺金属蛋白酶抑制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1283906C (en) * 1983-05-09 1991-05-07 Makoto Sunagawa .beta.-LACTAM COMPOUNDS AND PRODUCTION THEREOF
IL117440A0 (en) * 1995-03-31 1996-07-23 Pfizer Pyrrolidinyl hydroxamic acid compounds and their production process

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US493333A (en) * 1893-03-14 Air-heating furnace
CN1232451A (zh) * 1996-08-28 1999-10-20 普罗克特和甘保尔公司 取代的环状胺金属蛋白酶抑制剂

Also Published As

Publication number Publication date
KR100580056B1 (ko) 2006-05-12
EP1317428A1 (en) 2003-06-11
DE60118941D1 (de) 2006-05-24
MXPA03000363A (es) 2003-05-27
BR0112543A (pt) 2003-07-01
PE20020339A1 (es) 2002-04-23
ZA200300172B (en) 2004-04-07
EP1317428B1 (en) 2006-04-19
AR033543A1 (es) 2003-12-26
CA2415665A1 (en) 2002-01-24
AU2001276396A1 (en) 2002-01-30
JP2004504298A (ja) 2004-02-12
CN1443163A (zh) 2003-09-17
PA8522401A1 (es) 2002-09-30
KR20030024797A (ko) 2003-03-26
DE60118941T2 (de) 2006-12-21
US20020040048A1 (en) 2002-04-04
US6444829B1 (en) 2002-09-03
WO2002006224A1 (en) 2002-01-24
UY26844A1 (es) 2002-01-31
ATE323673T1 (de) 2006-05-15
ES2261443T3 (es) 2006-11-16

Similar Documents

Publication Publication Date Title
JP5518997B2 (ja) カテプシン阻害薬としてのプロリン誘導体
KR100568841B1 (ko) 엔도텔린-전환 효소의 억제제로서의 피롤리딘 유도체
EP2814822B1 (en) Novel pyrrolidine derivatives
CN1318402C (zh) 用作金属蛋白酶抑制剂的吡咯烷－2－羧酸酰肼衍生物
CN100406439C (zh) 作为金属蛋白酶抑制剂的吡咯烷衍生物
CN1938294B (zh) 吡咯烷-3,4-二甲酰胺衍生物
CN1443184A (zh) 嘧啶衍生物
HK1197672A (en) Novel pyrrolidine derivatives
HK1166322B (en) Proline derivatives as cathepsin inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070530

Termination date: 20090711